Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer

Molecular Oncology

Volumn 7, Issue 4, 2013, Pages 840-849

  Horiguchi, Shigeru ^a   Shiraha, Hidenori ^a   Nagahara, Teruya ^a   Kataoka, Jyunnro ^a   Iwamuro, Masaya ^a   Matsubara, Minoru ^a   Nishina, Shinichi ^a   Kato, Hironari ^a   Takaki, Akinobu ^a   Nouso, Kazuhiro ^a   Tanaka, Takehiro ^a   Ichimura, Koichi ^a   Yagi, Takahito ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Pancreaticoduodenectomy; Runt related transcription factor 3 (RUNX3); Survival

Indexed keywords

COMPLEMENTARY DNA; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 5; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX3;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL ASSAY; CELL GROWTH; CELL LINE; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; DNA TRANSFECTION; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN TISSUE; IC 50; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE; 5-FLUOROURACIL; 5-FU; ABC; ABCC; ADJUVANT CHEMOTHERAPY; ATP-BINDING CASSETTE; ATP-BINDING CASSETTE SUBFAMILY C; CAT; CDNA; CHLORAMPHENICOL ACETYLTRANSFERASE; COMPLEMENTARY DNA; FBS; FETAL BOVINE SERUM; MRP; MTT; MULTIDRUG RESISTANCE PROTEIN; PANCREATICODUODENECTOMY; RUNT-RELATED TRANSCRIPTION FACTOR 3 (RUNX3); RUNT-RELATED TRANSCRIPTIONAL FACTOR 3; RUNX3; SDS; SIRNA; SMALL INTERFERING RNA; SODIUM DODECYL SULFATE; SURVIVAL; TBS-T; TGF-Β; TRANSFORMING GROWTH FACTOR-Β; TRIS-BUFFERED SALINE WITH TWEEN 20;

CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOBLOTTING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RNA, SMALL INTERFERING;

EID: 84880737291     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.04.004     Document Type: Article

References (38)

1. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
2. Bae S.C., Choi J.K. Tumor suppressor activity of RUNX3. Oncogene 2004, 23:4336-4340.
3. Bergman A.M., Pinedo H.M., Talianidis I., Veerman G., Loves W.J., van der Wilt C.L., Peters G.J. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br. J. Cancer 2003, 88:1963-1970.
4. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J.Clin. Oncol. 1997, 15:2403-2413.
5. Chen M., Xue X., Wang F., An Y., Tang D., Xu Y., Wang H., Yuan Z., Gao W., Wei J., Zhang J., Miao Y. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. Oncol. Rep. 2012, 27:265-269.
6. Chuang L.S., Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010, 29:2605-2615.
7. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., Bennouna J., Bachet J.B., Khemissa-Akouz F., Pere-Verge D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N.Engl. J. Med. 2011, 364:1817-1825.
8. Dean M., Hamon Y., Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 2001, 42:1007-1017.
9. Efthimiou E., Crnogorac-Jurcevic T., Lemoine N.R. Pancreatic cancer genetics. Pancreatology 2001, 1:571-575.
10. Giovannetti E., Mey V., Nannizzi S., Pasqualetti G., Del Tacca M., Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther. 2006, 5:1387-1395.
11. Guo C., Ding J., Yao L., Sun L., Lin T., Song Y., Fan D. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int. J. Cancer 2005, 116:155-160.
12. Hagmann W., Jesnowski R., Faissner R., Guo C., Lohr J.M. ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology 2009, 9:136-144.
13. Hagmann W., Jesnowski R., Lohr J.M. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 2010, 12:740-747.
14. Hidalgo M. Pancreatic cancer. N.Engl. J. Med. 2010, 362:1605-1617.
15. Hong S.P., Wen J., Bang S., Park S., Song S.Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 2009, 125:2323-2331.
16. Ito K. RUNX3 in oncogenic and anti-oncogenic signaling in gastrointestinal cancers. J.Cell. Biochem. 2011, 112:1243-1249.
17. Jaffee E.M., Hruban R.H., Canto M., Kern S.E. Focus on pancreas cancer. Cancer Cell 2002, 2:25-28.
18. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
19. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
20. Kern S.E., Hruban R.H., Hidalgo M., Yeo C.J. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol. Ther. 2002, 1:607-613.
21. Konig J., Hartel M., Nies A.T., Martignoni M.E., Guo J., Buchler M.W., Friess H., Keppler D. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 2005, 115:359-367.
22. Langer R., Ott K., Feith M., Lordick F., Specht K., Becker K., Hofler H. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J.Surg. Oncol. 2010, 102:503-508.
23. Li J., Kleeff J., Guweidhi A., Esposito I., Berberat P.O., Giese T., Buchler M.W., Friess H. RUNX3 expression in primary and metastatic pancreatic cancer. J.Clin. Pathol. 2004, 57:294-299.
24. Li Q.L., Ito K., Sakakura C., Fukamachi H., Inoue K., Chi X.Z., Lee K.Y., Nomura S., Lee C.W., Han S.B., Kim H.M., Kim W.J., Yamamoto H., Yamashita N., Yano T., Ikeda T., Itohara S., Inazawa J., Abe T., Hagiwara A., Yamagishi H., Ooe A., Kaneda A., Sugimura T., Ushijima T., Bae S.C., Ito Y. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002, 109:113-124.
25. Maitra A., Hruban R.H. Pancreatic cancer. Annu. Rev. Pathol. 2008, 3:157-188.
26. Mimeault M., Brand R.E., Sasson A.A., Batra S.K. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005, 31:301-316.
27. Nakagawa T., Ido K., Sakuma T., Takeuchi H., Sato K., Kubota T. Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology 2009, 29:379-388.
28. Nakanishi Y., Shiraha H., Nishina S., Tanaka S., Matsubara M., Horiguchi S., Iwamuro M., Takaoka N., Uemura M., Kuwaki K., Hagihara H., Toshimori J., Ohnishi H., Takaki A., Nakamura S., Kobayashi Y., Nouso K., Yagi T., Yamamoto K. Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. BMC Cancer 2011, 11:3.
29. Noma B., Sasaki T., Fujimoto Y., Serikawa M., Kobayashi K., Inoue M., Itsuki H., Kamigaki M., Minami T., Chayama K. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int. J. Oncol. 2008, 33:1187-1194.
30. Nomoto S., Kinoshita T., Mori T., Kato K., Sugimoto H., Kanazumi N., Takeda S., Nakao A. Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer. Br. J. Cancer 2008, 98:1690-1695.
31. Oguri T., Achiwa H., Sato S., Bessho Y., Takano Y., Miyazaki M., Muramatsu H., Maeda H., Niimi T., Ueda R. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol. Cancer Ther. 2006, 5:1800-1806.
32. Okada S., Ueno H., Okusaka T., Ikeda M., Furuse J., Maru Y. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn. J. Clin. Oncol. 2001, 31:7-12.
33. Plasschaert S.L., de Bont E.S., Boezen M., vander Kolk D.M., Daenen S.M., Faber K.N., Kamps W.A., de Vries E.G., Vellenga E. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin. Cancer Res. 2005, 11:8661-8668.
34. Poplin E., Feng Y., Berlin J., Rothenberg M.L., Hochster H., Mitchell E., Alberts S., O'Dwyer P., Haller D., Catalano P., Cella D., Benson A.B. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J.Clin. Oncol. 2009, 27:3778-3785.
35. Rothenberg M.L., Moore M.J., Cripps M.C., Andersen J.S., Portenoy R.K., Burris H.A., Green M.R., Tarassoff P.G., Brown T.D., Casper E.S., Storniolo A.M., Von Hoff D.D. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 1996, 7:347-353.
36. Subramaniam M.M., Chan J.Y., Yeoh K.G., Quek T., Ito K., Salto-Tellez M. Molecular pathology of RUNX3 in human carcinogenesis. Biochim. Biophys. Acta 2009, 1796:315-331.
37. Tanaka M., Okazaki T., Suzuki H., Abbruzzese J.L., Li D. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer 2011, 117:744-751.
38. Wada M., Yazumi S., Takaishi S., Hasegawa K., Sawada M., Tanaka H., Ida H., Sakakura C., Ito K., Ito Y., Chiba T. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 2004, 23:2401-2407.